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Abstract
Background: Fluoxetine was the first molecule of a new generation of antidepressants, the
Selective Serotonin Re-uptake Inhibitors (SSRIs). It is recurrently the paradigm for the development
of any new therapy in the treatment of depression. Many controlled studies and meta-analyses
were performed on Fluoxetine, to improve the understanding of its real impact in the psychiatric
area. The main objective of this review is to assess the quality and the results reported in the meta-
analyses published on Fluoxetine.
Methods: Published articles on Medline, Embase and Cochrane databases reporting meta-analyses
were used as data sources for this review.
Articles found in the searches were reviewed by 2 independent authors, to assess if these were
original meta-analyses. Only data belonging to the most recent and comprehensive meta-analytic
studies were included in this review.
Results: Data, based on a group of 9087 patients, who were included in 87 different randomized
clinical trials, confirms that fluoxetine is safe and effective in the treatment of depression from the
first week of therapy. Fluoxetine's main advantage over previously available antidepressants (TCAs)
was its favorable safety profile, that reduced the incidence of early drop-outs and improved
patient's compliance, associated with a comparable efficacy on depressive symptoms. In these
patients, Fluoxetine has proven to be more effective than placebo from the first week of therapy.
Fluoxetine has shown to be safe and effective in the elderly population, as well as during pregnancy.
Furthermore, it was not associated with an increased risk of suicide in the overall evaluation of
controlled clinical trials.
The meta-analysis available on the use of Fluoxetine in the treatment of bulimia nervosa shows that
the drug is as effective as other agents with fewer patients dropping out of treatment.
Fluoxetine has demonstrated to be as effective as chlomipramine in the treatment of Obsessive-
Compulsive-Disorder (OCD).
Conclusion: Fluoxetine can be considered a drug successfully used in several diseases for its
favorable safety/efficacy ratio. As the response rate of mentally ill patients is strictly related to each
patient's personal characteristics, any new drug in this area, will have to be developed under these
considerations.
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Background
The release of fluoxetine was the beginning of a new era of
safe and effective treatment for patients with depres-
sion[1]. Fluoxetine was introduced into clinical use for the
treatment of patients with depression in 1988. Since then,
fluoxetine has become the most widely prescribed antide-
pressant drug in the world. In the following years, it was
approved for use in the treatment of patients with OCD
and bulimia nervosa. Other indications for its use, outside
of Italy, are Premenstrual Dysphoric Disorder (PMDD)
and major depression in children and adolescents.
Fluoxetine is a selective inhibitor of serotonin re-uptake;
it has little effect on other neurotransmitters [2]. It is well
absorbed after oral administration, with peak plasma con-
centrations observed after 6 to 8 hours. The parent com-
pound, fluoxetine, has an elimination half-life of 1 to 4
days, whereas the active metabolite, norfluoxetine, has an
half-life of 7 to 10 days[3]. This extended half-life appears
to protect against sporadic noncompliance [2] and against
the occurrence of withdrawal phenomena.
Objectives
Fluoxetine has been widely studied and described in the
scientific literature; its use has been reported in over 8,500
articles present in the most important literature databases
(Medline, Embase).
The objectives of this review were the following:
1. to evaluate the strength of the information available in
reviewed meta-analyses
2. to understand if the use of fluoxetine is clinically effec-
tive and safe compared with previously available drugs
3. to point out the drug's current role in the treatment of
diseases where fluoxetine is indicated.
This original review approach based on scientific evidence
seems the most appropriate to appreciate and understand
the main clinical characteristics of fluoxetine.
Methods
Searching and selection of studies
We attempted to identify all relevant meta-analyses on
fluoxetine as published and reported on Medline or
Embase databases.
Relevant meta-analytic trials, identified according to the
Gass definition of studies having characteristics summa-
rized in Table 1[4], were identified by searching the fol-
lowing electronic databases, accessed by Datastarweb
interface, using the following search strategy:
(i)MEDLINE (January 1966 to May 2003). The following
specific search for this review: [fluoxetin$ AND (metanal$
OR meta-anal$ OR meta ADJ analis$ OR meta ADJ ana-
lys$)] was performed
(ii) EMBASE (January 1988 to May 2003). The following
specific search for this review: [(fluoxetin$ AND
(metanal$ OR meta-anal$ OR meta ADJ analis$ OR meta
ADJ analys$))] was performed.
Documents reported in more than one database were
removed using the Datastarweb "remove duplicates"
function. A total of 438 unique records were identified.
The reference lists of all papers selected were inspected for
relevant studies where an original meta-analytic evalua-
tion was performed.
Major reviews published on the use of fluoxetine were
also inspected to assess the presence of relevant studies in
their references[5-9] as the Cochrane database.
Validity assessment
The abstract of each reference identified by the search was
independently evaluated by two of the authors (AR, PD)
to assess it's relevancy. All meta-analyses, where fluoxetine
was directly compared with placebo or with other drugs,
were eligible for this paper. A total of 25 articles were iden-
tified as suitable.
Data abstraction
In order to ensure that variation in results was not caused
by systematic errors in the design of selected studies, two
independent reviewers (AR, PD) assessed the methodo-
logical quality of each trial. Only the articles that met
these criteria were included. Reviewers were not blind to
the names of the authors, institutions and journal of pub-
lication. Any disagreement was discussed and decisions
were documented.
16 articles were not included in this paper:
Table 1: Essential steps in a systematic overview
Defining primary objective of the overview Defining the primary objective of any additional outcome measures
Systematic retrieval of the relevant studies Abstracting the quantitative information
Summarizing the evidence (using appropriate statistical methods if 
possible)
Interpreting the resultsAnnals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/2
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• 9 because fluoxetine was not analyzed separately from
other drugs[10-18]
• 3 because the same analysis was done in another more
recent, complete and updated article [19-21]
• 3 because the articles were reviews or randomized stud-
ies, even if titles suggest them as a meta-analysis[22-24]
• 1 because of the inconsistency between the methodol-
ogy reported in the scope and methodology of the
study[25]
Study characteristics
The 9 remaining articles, included in this paper, are sum-
marized in the following table (Table 2). These meta-anal-
yses evaluate the efficacy and/or safety of fluoxetine as a
treatment for major depression (MDD), obsessive-com-
pulsive disorder (OCD), bulimia nervosa, including preg-
nant and elderly populations
All outcomes (clinical improvement, remission, drop-
outs, adverse events) will be summarized using descrip-
tive statistics according to the method used in each study.
Results
Depression
Meta-analyses were based on original data from the US
IND database, on a virtual total of 87 studies of 9,084
potential patients using the drug.
Main results and study characteristics are summarized in
table 3.
The paper evaluating efficacy and safety of fluoxetine for
the short-term treatment of major depression[31], calcu-
lated the odds ratio analysis and the percentage of
responders (based on HDRS-17 improvement and CGI
outcome) compared with placebo and TCAs. All per-
formed analysis showed a statistically significant benefit
compared with placebo. No statistically significant differ-
ences were observed in the comparison with TCAs in
terms of efficacy.
In terms of discontinuations, significantly more dropouts
because of lack of efficacy were observed in the placebo
treated group. No significant difference was observed in
the comparison with TCAs.
Significantly more TCA treated patients discontinued the
studies than fluoxetine treated patients (on an average of
about 2 times more); more fluoxetine treated patients dis-
continued for the same reason.
Overall, significantly fewer patients on fluoxetine discon-
tinued treatment due to any adverse event compared (as
compared with TCAs), while a not-significant difference
in discontinuation rate for any reason was found vs
placebo.
Minor differences in the Fluoxetine group, regarding the
discontinuation rate for any reason, were not found to be
statistically significant, as compared to the placebo group.
The Beasley meta-analysis is on the safety of fluoxetine
compared with TCAs or placebo[28], substantially con-
firmed these results in terms of safety. It also adds some
interesting information about types of ADE and better
points out the role of fluoxetine's dosage. Considering
only events with an incidence above 5%, it was observed
in the TCA higher group, an incidence of cholinergic ADEs
(dry mouth, constipation, abnormal vision), sedation
(somnolence), dizziness and peresthesia, than in patients
using fluoxetine at dosages from 20 to 80 mg/die. Fluoxe-
tine treated patients showed a higher incidence of nausea,
insomnia, diarrhea, anorexia and rhinitis.
The same type of effects were substantially observed in the
comparison with placebo, but some of these (nervous-
ness, tremor, dizziness, dyspepsia) were not found to be
statistically higher than in placebo treated patients, when
only 20 mg/die dose was used.
The results of the analysis of discontinuations was consist-
ent with the one reported in the Bech study[31]. Further-
more, the drop out ratio due to adverse events of patients
using 20 mg/die of fluoxetine, was similar to the ratio
observed in the placebo-treated group.
These results, in terms of safety, are substantially con-
firmed by the Beasley study[29] where only a 20 mg/die
dosage was compared with placebo. Furthermore, these
fluoxetine treated patients demonstrated significantly
greater remission and response rates, mean changes on
HAMD-17 total score, anxiety/somatization, retardation
and cognitive disturbance factor score, than placebo
treated patients (p < 0,01).
All these results confirm the hypothesis that fluoxetine at
20 mg/die, the most commonly used effective dose in the
treatment of major depression, has an improved safety
and tolerability profile compared with higher doses of
fluoxetine.
The results of the Tollefson[34] study assess that the prob-
ability of achieving a clinical response, defined as HAMD-
21 score reduction from baseline of at least 50%, was sim-
ilar for both fluoxetine and placebo at the end of week 1.
However, by week 2 and after, the probability of responseAnnals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/2
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was greater for fluoxetine than placebo. These results chal-
lenged the current belief that a 3 to 4 week delay in the
onset of antidepressant action is to be expected.
Bulimia
A recent Cochrane group overview on the use of antide-
pressants in the treatment of bulimia nervosa, including
randomized placebo-controlled studies published until
2000, found that the use of drugs decreased the relative
risk of binge episodes. The only SSRI included in the anal-
ysis was fluoxetine (60 mg/die).
No statistically significant differential effect could be dem-
onstrated regarding efficacy among TCAs, SSRIs, MAOIs
and other classes of antidepressants.
The results of this meta-analysis show that patients treated
with antidepressants were more likely to prematurely
interrupt the treatment due to an adverse event. Patients
treated with TCAs dropped out for any reason more fre-
quently than patients treated with placebo. The opposite
was found with fluoxetine.
The authors conclude, "fluoxetine is the most systemati-
cally studied antidepressant agent. Even if it is not supe-
rior to other drugs in terms of efficacy, its better
tolerability may justify its use as a first line antidepressant
in bulimia nervosa. A daily dose of 60 mg is more effective
that the antidepressant doses of 20 mg. Eight weeks seems
to be an appropriate period to obtain a relevant clinical
improvement. If only a partial response is noted, an alter-
native therapeutic approach is indicated"[27].
OCD
In an analysis of the results from one fluoxetine and two
clomipramine studies, Jenije et al. found both treatments
to be effective with fluoxetine having fewer side effects. In
this study all three treatments (clomipramine, fluoxetine
and behavior therapy) were significantly effective for
OCD symptoms, anxiety and depression. Only behavior
therapy was not significantly effective for depressed
mood.
The authors conclude: "There are still not enough appro-
priate treatment studies available to determine statisti-
cally the superiority of any treatment"[26].
Elderly depression
Up to 4% of the elderly experience major depression and
as many as 44% experience depressive symptoms[27-31].
At least three published, population-based studies associ-
ate depression in the elderly patient with greater than
expected mortality[32-34].
The mean improvement in baseline-to-endpoint HAMD-
17 scores was significantly greater in fluoxetine (-7.9 ±
7.5) vs placebo-treated patients (-6.3 ± 7.1) (p < 0.01).
In the global population the anxious and nonanxious
subgroups, the analysis of psychomotor agitation, psy-
chotic anxiety or somatic anxiety, shows a consistent, but
not statistically significant, trend in the improvement rate
in fluoxetine treated patients as compared to the placebo
group.
The only adverse event most frequently reported by fluox-
etine treated patients wisthin the anxious subgroup was
nervousness (p=0.03). No statistically significant differ-
ences were reported between fluoxetine and placebo-
treated patients within the nonanxious subgroup.
The percentage of fluoxetine treated patients that discon-
tinued studies due to an adverse event (11.5%) was not
statistically different from placebo treated patients (9.6%)
(p=0.39)[33].
Suicide
Suicidal ideation, assessed using the item 3 of HAMD
scale which systematically rates suicidality, was evaluated
using data as belonging to clinical studies comparing
fluoxetine with TCAs and placebo. These were considered
as emergencies (any change from 0 or 1 to 3 or 4 in the
item during the double blind period) and as "worsening"
any increase from baseline. The pooled incidence of sui-
cidal acts was 0.3% for fluoxetine, 0.2% for placebo and
0.4% for TCAs; fluoxetine did not differ statistically from
any comparator group. Suicidal ideation emerged slightly
below the significance rate, less often than with placebo
(0.9% vs 2.6%: p=0.094) and numerically less often than
TCAs (1.7% vs 3.4%; p=0.102). The pooled incidence of
substantial suicidal ideation emergencies was 1.2% for
fluoxetine, 2.6% for placebo and 3.6% for TCAs; the inci-
dence was significantly lower with fluoxetine than with
placebo (p=0.042) and TCAs (p=0.001). The pooled inci-
dence of "worsening", as the pooled incidence of
improvement of suicidal ideation, did not differ between
groups except with the incidence of improvement with
fluoxetine (72.2%); which was statistically superior than
with placebo (54.8%; p < 0.001) [30].
Pregnancy
All meta-analyses previously reviewed did not include or
did not evaluate the safety of fluoxetine in pregnant
women. An ad-hoc meta-analysis on data belonging to
different sources, examined the increased risk for major
malformations following the use of fluoxetine during the
first trimester of pregnancy. The pooled relative risk and
95% confidence interval for major malformations does
not suggest an association between the use of fluoxetineAnnals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/2
Page 5 of 8
(page number not for citation purposes)
during the first trimester of pregnancy and the increased
risk of major malformations. The authors conclude that
the use of fluoxetine during the first trimester of preg-
nancy is not associated with measurable teratogenic
effects in humans[26].
Discussion
Fluoxetine is a widely and well-known drug successfully
used in treating several diseases. Its unique combination
of efficacy and its safety profile explains its key role in the
history of the pharmacotherapy of several diseases. Fluox-
etine could be considered the standard comparator for the
development of new drugs to be used in the treatment of
serious and socially invasive pathologies as Major Depres-
Table 2: Summary of studies characteristics
Study Number of Studies 
Patients on Flx
Comparator(s) Disease and Patient 
Population
Methodology
Addis 2000 [36] 4 studies 367 pts TCAs Pregnant in the first 
trimester
Medline and Embase search up to August 1996. REPROTOX and 
Current content up to November 1996. Manual retrieve from 
conferences acts.
Only cohort studies eligible for the analysis. Weighted average of 
fetal risk for major malformations.
Mantel-Haenszel odds ratio and overall 95% confidence interval.
Bacaltchuk 2003 
[37]
16 studies 449 pts Placebo TCAs MAOIs Bulimia nervosa MEDLINE (1966 to December 2000), EMBASE (1980-December 
2000), PsycLIT (to December 2000), LILACS & SCISEARCH (to 
1997) search.
Randomized, placebo-controlled trials in which antidepressant 
medications were compared to placebo to reduce the symptoms 
of bulimia nervosa in patients of any age or gender.
The main objective was the evaluation of antidepressant 
medications as clinically effective for the treatment of bulimia 
nervosa.
Beasley 2000 (1) 
[38]
25 studies 1258 pts Placebo TCAs Major Depressive Disorder Data from US IND double-blind, randomized controlled clinical 
trials. 
Spontaneously reported treatment emergent adverse events 
(regardless of cause), reasons for discontinuation, and events 
leading to discontinuation were compared between groups.
Mantel-Haenszel incidence difference after Cochran test; Der-
Simonian-Laird test, when appropriate.
Beasley 2000 (2) 
[39]
3 studies 233 pts Placebo Major Depression Data from US IND double-blind, randomized controlled clinical 
trials using fluoxetine fixed dose 20 mg/die on adult patients.
Only efficacy data (response rate, depression improvement) 
included in this review because safety data are included in the 
Beasley 2000 article [28].
Whitehead and Whitehead method. Mantel-Haenszel incidence 
difference stratified by study. Der-Simonian-Laird test, when 
appropriate
Beasley 1992 [40] 17 studies 1765 pts TCAs Placebo Depression Suicidal acts Data from US IND double-blind, randomized controlled clinical 
trials up to December 1989.
Incidence of suicides. Suicide ideation acts and worsening in 
suicidal ideation.
Binomial unconditional Mantel-Haenszel estimate. Mantel-
Haenszel adjusted incidence difference. Pearson's chi-square test.
Bech 2000 [41] 30 studies 4120 pts TCAs Placebo Major Depression Short 
term effect
Data from US IND double-blind, randomized controlled clinical 
trials up to December 1992.
Efficacy and discontinuations rate for acute treatment. Log odds 
ratio for binary data. Effect size analysis. Whitehead and 
Whitehead method.
Cox 1993 [42] 25 studies Clomipramine Behavior 
therapy
OCD MEDLINE (1975 to 1991), PsycLIT (1975 to 1991) search. Studies 
excluded if case studies, review paper, contained previously 
published data or did not contain the dependent variables of 
interest (severity of OCD symptoms, anxious and depressed 
mood assessed by a commonly used numeric scale). Effect size 
and Z-Score.
Hoog 1999 [43] 6 studies 746 pts Placebo Depression Pts over 55 Data from US IND double blind, randomized controlled clinical 
trials up to December 1998.
Changes in HAMD-17 total score, anxiety, agitation, and insomnia 
during treatment of depression. Treatment emergent adverse 
events and reasons for discontinuation. Mantel-Haenszel 
incidence difference with Sato's correction after Cochran test. 
Der-Simonian-Laird test, when appropriate.
Tollefson 1994 
[44]
6 studies 962 pts Placebo Major Depression Data from US IND double blind, randomized controlled clinical 
trials.
Time of onset of antidepressant action and patient's 
discontinuation rates.
Least squares means and standard error for the description of 
response variables.
Cochran-Mantel-Haenszel statistic stratified by study. 
Kaplan.Meier estimate of the time to response and remission. 
Wilcoxon test and log rank test to evaluate the difference 
between the two distributions.Annals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/2
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sion, Bulimia Nervosa, Obsessive Compulsive Disorder,
Premenstrual Dysphoric Disorder, as it confirms its effec-
tiveness in elderly, children, adolescents and pregnant
women suffering from depression.
All the above studies on depressed patients tend to under-
estimate the efficacy pattern of fluoxetine, mainly because
of the type of studies considered. In fact the drop-out rate
is always higher in the placebo arm than in the fluoxetine
one, so that those patients with a placebo response com-
pleted the study and increased the revealed effectiveness
of placebo. An even higher increase in the response rate or
in the efficacy score in the fluoxetine arm has to be added
to the greatest number of patients that, consistently
between different studies, completed the trial period.
The dose showing the better effectiveness was 20 mg/die.
Fluoxetine results also effective and safe for the treatment
of Bulimia Nervosa and OCD.
Furthermore, the use of fluoxetine has shown a general
improvement in the suicidal actions and ideations in
depressed patients.
The most commonly reported side effects of fluoxetine
include sexual dysfunction, headache and nausea, but for-
tunately, even in the small minority of patients who have
them, such effects generally disappear after about 2 weeks,
although, as with other antidepressants, sexual dysfunc-
tion can persist[35].
The incidence of spontaneous adverse events resulted
quite impressive, but the vast majority of depressed
patients were proud to report their symptoms to physician
in a controlled study environment. If we compare the true
incidence of adverse events, only dry mouth appeared in
Table 3: Study characteristics and main results
Study Main results
Beasley 2000 (1) [28] TCAs vs Flx (doses 20–80 mg/die): greatest incidence of cholinergic ADEs (dry mouth, constipation, abnormal vision), 
sedation (somnolence), orthostatic (dizziness) and paresthesia in TCAs group.
Flx (doses 20–80 mg/die) vs pla: greatest incidence of gastrointestinal ADEs (dyspepsia, nausea, anorexia, diarrhea), 
sedating (somnolence, asthenia), activation (insomnia, nervousness, anxiety), tremor, sweating, dizziness in Flx group.
Flx 20 mg die vs pla: nervousness, tremor, dizziness, dyspepsia no more common than pla.
Total drop-out: flx (20–80) 35.2%, TCAs 47.9% (p < 0.001.); total drop-out: flx (20–80) 37.7%, pla 38.2% (p = n.s.); total 
drop-out: flx (20) 29.0%, pla 27.5% (p = n.s.);
Drop-out for ADE: flx (20–80) 16.4%, TCAs 31.4% (p < 0.001); drop-out for ADE: flx (20–80) 13.7%, pla 6.0% (p < 0.001); 
drop-out for ADE: flx (20) 9.0%, pla 7.7% (p = n.s.);
Drop-out for lack of efficacy: flx (20–80) 9.5%, TCAs 7.8% (p = n.s.); drop-out for lack of efficacy: flx (20–80) 10.6%, pla 
22.3% (p < 0.001); drop-out for lack of efficacy: flx (20) 8.8%, pla 11.3% (p = 0.029);
Beasley 2000 (2)[29] For minimal therapeutic exposure HDRS-17 responders flx v pla: +24.8%; p < 0.01; HDRS-17 remitters (HDRS ≤ 7 at last 
visit) flx v pla: +17.5%; p < 0.01.
For intent-to-treat responders flx v pla: +20.5%; p < 0.01; remitters flx v pla: +13.3%; p < 0.01.
Bech 2000[31] HDRS-17 responders flx v pla: +21.4% (efficacy analysis); +13.6% intention to treat analysis. Overall Odds ratio = 2.22 
(95% CI: 1.83–2.70; p < 0.01).
CGI responders flx v pla: +24.3% (efficacy analysis); +14.3% (intention to treat analysis). Overall Odds ratio = 2.20 (95% 
CI: 1.83–2.66; p < 0.01).
Total drop-out: Odds ratio flx vs TCAs: 0.75 (95% CI: 0.62–0.90; p < 0.01).
Drop-out for adverse event: Odds ratio flx vs TCAs: 0.53 (95% CI: 0.42–0.67; p < 0.01).
Tollefson 1994[34] Week of Therapy HAMD Total Flx pts (n = 930) Pla pts (n = 468) p
0 Baseline 25.5 25.5 .740
1 Change -5.7 -4.6 0.016
2 Change -8.1 -6.5 0.003
3 Change -9.7 -7.4 <0.001
4 Change -10.5 -8.0 <0.001
5 Change -11.3 -8.3 <0.001
6 Change -11.7 -8.3 <0.001
Flx = Fluoxetine; TCAs = Tricyclic Antidepressant Agents; Pla = placebo ADE = Adverse Drug Event; HDRS-17 = 17-item Hamilton Depression 
Rating Scale; HAMD = 21-item Hamilton Depression Rating ScaleAnnals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/2
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over 50% of TCAs treated patients; as depressive patients
often have hypochondriacal attitudes, when they know
they are in a clinical trial, their answers to specific ques-
tions regarding their physical conditions overestimate
their feelings compared with non-trial environment. A
confirmation about this belongs to the fact that physical
symptoms were often reported by the placebo treated
patients, in some cases statistically more often than in the
fluoxetine arm (back pain arthralgia)[29].
Conclusion
All data from the above meta-analyses confirm that in the
treatment of patients with major depression, fluoxetine is
equally effective as, and has a distinctly more benign side-
effect profile and lower rates of discontinuation than the
TCAs, is safer in overdose and easier and simpler for
patients to use and physicians to prescribe.
Fluoxetine was found to be similar in side-effect profile to
the other SSRIs, including paroxetine, sertraline, fluvox-
amine and citalopram. Fluoxetine has demonstrated the
least need for dose titration of any available antidepres-
sant. Most of the studies comparing SSRIs were 6 to 8
weeks in duration, but one study comparing fluoxetine
and sertraline followed up 57 patients for 8 months and
found the efficacy was maintained with a low incidence of
adverse events[8].
In summary, fluoxetine is effective in treating all degrees
of depression and is clearly better tolerated (ie, has a more
benign adverse-events profile) and safer in cases of over-
dose than the older antidepressant drugs[8]. Response to
pharmacotherapy is likely incremental, and the rate of
response highly individualized, so more detailed atten-
tion to patient heterogeneity and early response patterns
has to be studied in the development of any new treat-
ment for depressive pathologies.
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